Lynn Mailloux, MD
Cardiovascular Disease · New York, NYNPI 1477727410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Abbott at 44.3% of the total. Reporting peaked in 2019 at $229 and has fallen 78.2% since, to $50 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 7 payments — averaging $74.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$229
- Boston Scientific$129
- Impulse Dynamics (USA) Inc.$88
- Lexicon Pharmaceuticals, Inc.$50
- Merck$22
What the payments were for
- Food & beverage$49796%
- Education$224%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $229 |
| Boston Scientific | 1 | $129 |
| Impulse Dynamics (USA) Inc. | 1 | $88 |
| Lexicon Pharmaceuticals, Inc. | 2 | $50 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$161
- EMBLEM$129
How this compares
$518 in reported general payments places this provider in the 30th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $210,042 |
| Repatha SureclickEvolocumab | 78 | $72,570 |
| XareltoRivaroxaban | 30 | $43,490 |
| EntrestoSacubitril/Valsartan | 35 | $41,705 |
| FarxigaDapagliflozin Propanediol | 24 | $22,658 |
| Praluent PenAlirocumab | 31 | $21,498 |
| JardianceEmpagliflozin | 11 | $13,587 |
| Rosuvastatin Calcium | 304 | $4,696 |
| Metoprolol Succinate | 229 | $3,506 |
| Losartan Potassium | 257 | $3,074 |
| Atorvastatin Calcium | 255 | $2,721 |
| Ezetimibe | 101 | $2,461 |
| Telmisartan | 40 | $1,371 |
| Candesartan Cilexetil | 24 | $1,249 |
| Amlodipine Besylate | 162 | $1,121 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.